The FDA has approved Itvisma for the treatment of children two years and older, teens and adults living with spinal muscular ...

On 25 November 2025, Novartis Pharmaceuticals conducted a study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with ...

Novartis secured approval for its drug to treat certain patients diagnosed with spinal muscular atrophy from the Food and Drug Administration.

Spinal muscular atrophy (SMA) is a genetic disease that affects the nervous system and, mostly, the muscles it controls. It weakens muscles and can lead to problems breathing, eating, and walking. SMA ...

Basel: Novartis has received approval from the US Food and Drug Administration (FDA) for Itvisma (onasemnogene ...

Muscles are made up of proteins. Myosin, a fibrous protein, serves as a molecular motor and converts the chemical energy stored inside our body into mechanical energy. The synergistic association ...

"The most apparent take-away from the study findings is that a model of developmental therapy focusing on frequency, intensity, and variability of activity, exercise, and self-driven exploration may ...

Animals that hibernate are incredibly resilient. They can spend months without food or water, muscles refusing to atrophy, body temperature dropping to near freezing as their metabolism and brain ...